Ramius Advisors’s Starling Oncology STLN Stock Holding History

Ramius Advisors’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-65,724	Closed	-$655K	–	301
2021 Q1	$655K	Buy	+65,724	New	+$700K	0.17%	142

Other funds holding STLN

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Millennium Management

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Ramius Advisors's STLN Position: Q2 2021 in Review

Ramius Advisors sold out of Starling Oncology (STLN) in Q2 2021, closing a stake of 65,724 shares — an estimated $655K sold.

Ramius Advisors first reported a position in STLN in Q1 2021 and held it in 1 quarter. The position peaked at $655K in Q1 2021. 53 funds tracked by Wall St. Rank hold STLN as of Q2 2021.

Ramius Advisors reported no remaining Starling Oncology position as of Q2 2021 after selling out during the quarter.
Ramius Advisors sold 65,724 Starling Oncology shares in Q2 2021, an estimated $655K.
Ramius Advisors first reported a position in Starling Oncology in Q1 2021 and held it in 1 quarter.
Ramius Advisors's Starling Oncology position peaked at $655K in Q1 2021.
53 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2021.

Based on Ramius Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.